US 12,258,597 B2
Methods and compositions for therapeutic protein delivery
Andrew Baik, Scarsdale, NY (US); Katherine Cygnar, New York, NY (US); and Maria Praggastis, Cortlandt Manor, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Appl. No. 16/968,452
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
PCT Filed Feb. 7, 2019, PCT No. PCT/US2019/017116
§ 371(c)(1), (2) Date Aug. 7, 2020,
PCT Pub. No. WO2019/157224, PCT Pub. Date Aug. 15, 2019.
Claims priority of provisional application 62/777,683, filed on Dec. 10, 2018.
Claims priority of provisional application 62/627,721, filed on Feb. 7, 2018.
Prior Publication US 2020/0399623 A1, Dec. 24, 2020
Int. Cl. C12N 9/26 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01); A61P 3/00 (2006.01); C07K 16/28 (2006.01)
CPC C12N 9/2408 (2013.01) [A61K 48/005 (2013.01); A61P 3/00 (2018.01); C07K 16/2881 (2013.01); C07K 16/2896 (2013.01); C12Y 302/0102 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2319/33 (2013.01); C12N 2750/14143 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A multidomain therapeutic protein comprising a first delivery domain, a second delivery domain, and an enzyme domain, wherein the first delivery domain binds human transferrin receptor (hTfR), and wherein the second delivery domain comprises a single-chain variable fragment (scFv) that binds CD63, wherein the scFv that binds CD63 comprises the sequence set forth in SEQ ID NO: 2.